Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
The newly granted patents cover composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines. Newly granted patents span major markets, with anticipated expiration dates ranging from 2033 to 2040 depending on the specific case and local rules, without accounting for any potential extensions.
Patents granted include:
'These newly granted and allowed patents not only expand the breadth and depth of our intellectual property portfolio but also enhance the long-term commercial potential of our Superkine programs,' said Fahar Merchant, Ph.D., President and CEO of Medicenna. 'Notably, the patent covering IL-2 superagonists in combination with anti-PD1 antibodies provides important coverage for MDNA11, which is being evaluated in the ongoing Phase 1/2 ABILITY-1 study, reinforcing both the clinical rationale and commercial potential. Furthermore, protection granted to a novel formulation of bizaxofusp (MDNA55), used in the Phase 2b recurrent glioblastoma clinical trial, solidifies its commercial exclusivity for treatment of brain cancers as we pursue potential partnering of this Phase 3 ready asset. By strengthening long-term protection for our proprietary IL-2 and IL-4 assets across key jurisdictions, we are laying the foundation for durable competitive advantage and sustained shareholder value. We look forward to sharing additional clinical data from the ABILITY-1 clinical trial during the balance of this calendar year.'
Medicenna's global IP portfolio now comprises 86 granted or allowed patents, supporting a robust and diverse clinical pipeline.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically 'cold' tumors.
For more information, please visit
www.medicenna.com
, and follow us on
X
and
.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook, intellectual property protection, clinical and commercial potential, competitive position and shareholder value creation or or other statements that are not historical facts. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expect', 'believe', 'seek', 'potentially' and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
ir@medicenna.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Financière de Tubize – 2025 half-year financial report
By GlobeNewswire Published on August 2, 2025, 11:00 IST Half-year financial report 2025 Regulated information 2 August 2025 The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the website Profit for the first half of 2025: € 95.6 million (€ 92.9 million in 2024, + 2.8%), Dividend received from UCB: € 98.1 million (€ 1.39 per share, an increase of 2.2% compared to the previous year), 2024 Dividend paid to Financière de Tubize's shareholders in 2025 of € 46.3 million (€ 1.04 per share, an increase of 7.22% compared to the previous year), Acquisition, in 2025, of 24,487 UCB shares, for a total amount of € 4.37 million, at an average price of € 178.3. Our stake in UCB has increased from 36.27% on 31 December 2024 to 36,28% on 30 June 2025, Decrease of outstanding bank borrowings from € 41.3 million at 31 December 2024 to € nil at 30 June 2025. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
SHARC Energy Announces Update on Convertible Debenture Financing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) ('SHARC Energy' or the 'Company') would like to announce its intention to complete a non-brokered private placement of secured convertible debentures (each, a 'Debenture') with a principal amount of up to $1,500,000 (the 'Offering'). The Debenture is secured against all present and after acquired assets of the Company. The Debentures will bear interest at a rate of 8.0% per annum and mature on the date that is 24 months from the date of issuance (the 'Maturity Date'). The holder will have the option to extend the Maturity Date for a period of 12 months and receive all accrued and unpaid interest in cash or in common shares in the capital of the Company ('Common Shares') at a price of $0.10 per Common Share (the 'Conversion Price'). Additionally, the outstanding principal amount owed under a Debenture may be converted into Common Shares at the Conversion Price at the option of the holder at any time on or prior to the last business day prior to the Maturity Date. The Company may from time to time, in its sole discretion, prepay all or a part of the principal amount and accrued interest without penalty. The Company intends to use the proceeds from the Offering for working capital purposes as the Company continues to fulfil the shipment and delivery of SHARC and PIRANHA WET systems. The Company may pay a finder's fee in connection with the Offering to eligible arm's length finders in accordance with applicable securities laws and the policies of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable Canadian securities laws. The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933 , as amended (the 'U.S. Securities Act'), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. The above Offering is being carried out in place of the previously announced offering on June 20, 2025, which is now cancelled. About SHARC Energy SHARC International Systems Inc. is a world leader in energy recovery from the wastewater we send down the drain every day. SHARC Energy's systems recycle thermal energy from wastewater, generating one of the most energy-efficient and economical systems for heating, cooling & hot water production for commercial, residential, and industrial buildings along with thermal energy networks, commonly referred to as 'District Energy'. SHARC Energy is publicly traded in Canada (CSE: SHRC), the United States (OTCQB: INTWF) and Germany (Frankfurt: IWIA) and you can find out more on our SEDAR profile. Learn more about SHARC Energy: Website | Investor Page | LinkedIn | YouTube | PIRANHA | SHARC ON BEHALF OF THE BOARD Fred Andriano Chairman The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified using words such as 'anticipate', 'plan', 'estimate', 'expect', 'may', 'will', 'intend', 'should', and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. SHARC Energy's actual results could differ materially from those anticipated in this forward-looking information because of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. SHARC Energy believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether because of new information, future events or otherwise, except as required by applicable securities legislation. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
2 hours ago
- Business Upturn
AI-Powered Crypto OZAK AI Enters the Spotlight as $1,500,000 Raised in Presale
By GlobeNewswire Published on August 2, 2025, 07:00 IST ROAD TOWN, British Virgin Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) — OZAK AI Raises above $1,500,000 in Presale and it's currently priced at $0.005. Visa's growing interest in stablecoins has shifted the focus toward AI-integrated cryptocurrencies. Ozak AI is one among them and is rapidly developing attention. Its ongoing presale has already sold over 66.2 million tokens and raised over 1.53 million. This traction is an indication of a market turning point where blockchain projects featuring AI capabilities are pressing to be relevant to the masses. With clear goals and token transparency, Ozak AI stands out during a pivotal moment. Market participants are now moving toward platforms that blend automation, decentralization, and predictive financial tools. The crypto market, driven by technological innovation, continues aligning with AI and blockchain synergy. The rise of hybrid platforms such as Ozak AI is the next step in supporting the stablecoin space. These machine-learning models promote faster and data-driven models of approaches to the market. Youtube embed: Next 500X AI Altcoin Ozak AI's Predictive Models and Automated Governance Gain Traction Ozak AI utilizes predictive analytics and automated governance to run its decentralized ecosystem. The company uses reinforcement learning and neural networks to analyze large financial data. Such a system allows extensive market predictions and optimal risk control. Users can enjoy real-time alerts, price pattern recognition, and automation of smart contracts. The AI framework conducts the analysis of proposals, delegates voters, and identifies anomalies. These abilities ensure the transparency and operational effectiveness of its decentralized ecosystem. Its decision-making process and rules use smart contracts in governance structures. There is no central authority, and decision-making is in the hands of the token holders who vote on-chain. The system also helps address threats, such as Sybil attacks, by verifying identities and behaviors with the help of AI. $OZ Token Fuels a Decentralized Financial Infrastructure The $OZ token is used to buy, stake and deploy models. Holders of the token are also entitled to vote on security and ecosystem changes. The token will be distributed in phases, and the present price stands at $0.005. The price will be raised to $0.01 in the next phase. A target of 1 is set, which is in line with the maturity of the networks and deployment of features. Its validation entails the network using a staking mechanism to facilitate its incentives. This method promotes efficiency and speed in the execution of smart contracts via Arbitrum Orbit. It also improves the capacity of the DeFi ecosystem to handle a large amount of data traffic. Moreover, the EigenLayer integration with AVS provides safe certification of AI regulation and monetary exchange. Data storage works via DePIN, eliminating one point of failure. Ozak AI Reinforces AI-Blockchain Integration in DeFi and Trading AI agents optimize market entry and exit strategies in volatile environments. These agents examine macroeconomic indicators and trading volumes and price fluctuations. Consequently, traders obtain better timing as well as more accurate markets. Real-time and automated alerts allow an immediate response to market action. Machine learning models continuously adapt and enhance trading accuracy. This adaptability gives Ozak AI a distinct position in the fast-evolving crypto trading space. With stablecoin backing increasing, AI-enhanced platforms, such as Visa, now fill gaps left by traditional tools. Ozak AI combines security, automation, and financial prediction into one system. For more information about Ozak AI, visit the links below. Website: Twitter/X: Telegram: Media Contact: Andres Brinc [email protected] Disclaimer: This content is provided byOzak AI. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
